← Eichor
Study identifier: NCT07297966 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of the Clinical Efficacy of Antrrix Probiotics in Improving Recurrent Respiratory Infections in Infants and Young Children

Condition: Recurrent Respiratory Tract Infections  ·  Sponsor: Min-Tze LIONG

PhasePhase 2
Planned participants120
Who can joinAll sexes, 1 Day to 6 Years
Healthy volunteersNo

About this study

This study is an 8-weeks, randomized controlled trial involving children under 6 years of age who meet clinical diagnostic criteria for RRTI. Participants are randomized to receive either probiotic or placebo. The primary clinical outcomes assessed are duration and frequency of respiratory symptoms and quality of life. To investigate potential mechanisms, stool samples were collected pre- and post-intervention for metagenomics gene sequencing to analyze changes in gut microbiota composition and identify specific bacterial taxa associated with clinical improvements.

This description comes directly from the study's public registry record.

Talk to the study team

Min-Tze Liong, Ph.D.  ·  6046532114  ·  mintze.liong@usm.my

Jie Yuan, M.Sc.  ·  822137027899  ·  peanut.yuan@diprobio.com

Always discuss trial participation with your own doctor first.

Locations (2)

Xinyi City People's HospitalXingyi, Guangdong, ChinaRecruiting
Universiti Sains MalaysiaGeorge Town, Pulau Pinang, MalaysiaNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07297966